Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

181. Addendum to Commission A13-17 (vildagliptin/metformin)

Addendum to Commission A13-17 (vildagliptin/metformin) 1 Translation of addendum A13-31 “Addendum zum Auftrag A13-17 (Vildagliptin/Metformin)” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum to Commission A13-17 (vildagliptin/metformin) 1 Addendum IQWiG Reports – Commission No. A13-31 Commission: Version: Status (...) : A13-31 1.0 29 August 2013 Addendum Addendum to Commission A13-17 Version 1.0 (vildagliptin/metformin) 29 August 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic: Addendum to Commission A13-17 (vildagliptin/metformin) Commissioning agency: Federal Joint Committee Commission awarded on: 6 August 2013 Internal Commission No.: A13-31 Address of publisher: Institute for Quality and Efficiency

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

182. Addendum to Commission A13-03 (sitagliptin/metformin)

Addendum to Commission A13-03 (sitagliptin/metformin) 1 Translation of the document “Addendum zum Auftrag A13-03 (Sitagliptin/Metformin)” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum to Commission A13-03 (sitagliptin/metformin) 1 Addendum IQWiG Reports – Commission No. A13-29 Commission: Version: Status: A13-29 (...) 1.0 29 August 2013 Addendum to Commission A13-03 Version 1.0 (sitagliptin/metformin) 29 August 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic: Addendum to Commission A13-03 (sitagliptin/metformin) Commissioning agency: Federal Joint Committee Commission awarded on: 6 August 2013 Internal Commission No.: A13-29 Address of publisher: Institute for Quality and Efficiency in Health Care Im

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

183. Vildagliptin/metformin - Benefit assessment according to § 35a Social Code Book V

Vildagliptin/metformin - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Vildagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 27 June 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-17 Vildagliptin/metformin (...) – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-17 Version 1.0 Vildagliptin/metformin – Benefit assessment acc. to § 35a Social Code Book V 27 June 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Vildagliptin/metformin – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 28

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

184. Sitagliptin/metformin - Benefit assessment according to § 35a Social Code Book V

Sitagliptin/metformin - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Sitagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 27 June 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-03 Sitagliptin/metformin (...) – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-03 Version 1.0 Sitagliptin/metformin – Benefit assessment acc. to § 35a Social Code Book V 27 June 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin/metformin – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 27

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

185. Saxagliptin/metformin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V

Saxagliptin/metformin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Saxagliptin/Metformin (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 27 June 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A13-12 Saxagliptin/metformin (new therapeutic indication) – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-12 Version 1.0 Saxagliptin/metformin (new therapeutic indication) – Benefit assessment acc. to § 35a Social Code Book V 27 June 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin (new therapeutic indication

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

186. Addendum to Commission A12-16 (saxagliptin/metformin)

Addendum to Commission A12-16 (saxagliptin/metformin) 1 Translation of the document “Addendum zum Auftrag A12-16 (Saxagliptin/metformin)”, (Version 1.0; Status: 12 April 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum to Commission A12-16 (saxagliptin/metformin) 1 Addendum 12 April 2013 1.0 Commission: A13-14 Version: Status: IQWiG Reports (...) – No. 161 Addendum to Commission A12-16 Version 1.0 (saxagliptin/metformin) 12 April 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic: Addendum to Commission A12-16 (saxagliptin/metformin) Contracting agency: Federal Joint Committee Date of commission: 27 March 2013 Internal Commission No.: A13-14 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

187. Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V

Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Saxagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 13.02.2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A12-16 Saxagliptin/metformin – Benefit (...) assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A12-16 Version 1.0 Saxagliptin/metformin – Benefit assessment acc. to § 35a Social Code Book V 13.02.2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 15.11.2012 Internal

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

188. Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus

Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation CADTH. Linagliptin-metformin (Jentadueto - Boehringer Ingelheim (Canada) Ltd.) indication: type 2 diabetes mellitus. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2013 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that linagliptin/metformin (Jentadueto) be listed for patients if the following clinical criterion is met: Patients for whom insulin is not an option and who are already

2013 Health Technology Assessment (HTA) Database.

189. Randomised controlled trial: Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)?

Randomised controlled trial: Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)? Article Text Therapeutics Randomised controlled trial Should

2013 Evidence-Based Medicine

190. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. (Abstract)

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately (...) controlled with metformin.We undertook this 52 week, randomised, double-blind, active-controlled, phase 3 non-inferiority trial at 157 centres in 19 countries between Aug 28, 2009, and Dec 21, 2011. Patients aged 18-80 years with type 2 diabetes and glycated haemoglobin A1c (HbA1c) of 7·0-9·5% on stable metformin were randomly assigned (1:1:1) by computer-generated random sequence via an interactive voice or web response system to receive canagliflozin 100 mg or 300 mg, or glimepiride (up-titrated to 6

2013 Lancet Controlled trial quality: predicted high

191. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus (Abstract)

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus To investigate the efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin.This was a 24-week, randomized, double-blind, placebo-controlled study. Patients with T2DM (N = 438) with haemoglobin A1c (HbA1c) of 7.0-10.0% and fasting plasma glucose (FPG) <15 mmol/l (...) mg bid, 50 mg qd or placebo, respectively. Two patients in the vildagliptin 50 mg qd and one in the placebo group reported serious AEs, which were not considered to be related to the study drug; one incidence of hypoglycaemic event was reported in the vildagliptin 50 mg bid group.Vildagliptin as add-on therapy to metformin improved glycaemic control and was well tolerated in Chinese patients who were inadequately controlled by metformin only.© 2012 Blackwell Publishing Ltd.

2013 EvidenceUpdates Controlled trial quality: uncertain

192. Systematic review with meta-analysis: Metformin may not reduce cardiovascular risk or all-cause mortality

Systematic review with meta-analysis: Metformin may not reduce cardiovascular risk or all-cause mortality Metformin may not reduce cardiovascular risk or all-cause mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin may not reduce cardiovascular risk or all-cause mortality Article Text Online articles Systematic review with meta-analysis Metformin may not reduce cardiovascular risk or all-cause mortality Matteo Monami

2013 Evidence-Based Medicine

193. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti (Abstract)

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti To test the hypothesis that glycaemic control achieved when switching sitagliptin to exenatide twice daily plus metformin is non-inferior to adding exenatide twice daily to sitagliptin and metformin.Patients with Type 2 diabetes inadequately (...) controlled with sitagliptin plus metformin were randomly assigned to 20 weeks of treatment with twice-daily exenatide plus placebo and metformin (SWITCH, n = 127) or twice-daily exenatide plus sitagliptin and metformin (ADD, n = 128).Non-inferiority (0.4% margin) of SWITCH to ADD treatment, measured by change in HbA(1c) from baseline to week 20, was not shown {between-treatment difference in least-squares mean [95% CI 3 mmol/mol (0.30%)] [0.8-5.8 (0.07-0.53)]}. A greater reduction (P = 0.012) in HbA(1c

2012 EvidenceUpdates Controlled trial quality: uncertain

194. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

195. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. (Abstract)

Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive-aged women. Apart from infertility, women with PCOS often have other endocrine disorders, including insulin resistance, hyperinsulinaemia and hyperandrogenism. Metformin,combined with clomiphene citrate (CC), has been shown to be more effective in ovulation induction when compared (...) with clomiphene citrate alone. The optimal duration for metformin pretreatment before initiation of clomiphene citrate, however, is unknown.To determine the effectiveness of short-course (less than four weeks) metformin plus CC versus long-course (four weeks or more) metformin plus CC with regard to ovulation and achievement of pregnancy in infertile women with PCOS.We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE

2012 Cochrane

196. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes. (Abstract)

Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes. 22801704 2012 09 24 2012 07 17 1539-3704 157 2 2012 Jul 17 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes. JC2-13 10.7326/0003-4819-157-2-201207170-02013 Chatterjee Saurav S eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 BMJ. 2012;344:e1369 22411919 2012 7

2012 Annals of Internal Medicine

197. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets Full Text available with Trip Pro

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%.In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run (...) -in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups.Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change -1.3% from 7.7% at start), whereas 39% (n = 323) did not (-0.6% from 8.3% at start

2012 EvidenceUpdates Controlled trial quality: uncertain

198. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial (Abstract)

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We conducted two randomised, double-blind, three-arm 24-week trials in treatment-naïve patients to compare dapagliflozin plus metformin, dapagliflozin alone and metformin alone.Eligible patients had baseline HbA1c 7.5-12%. Each (...) trial had three arms: dapagliflozin plus metformin, dapagliflozin monotherapy and metformin monotherapy. Dapagliflozin in combination and as monotherapy was dosed at 5 mg (Study 1) and 10 mg (Study 2). Metformin in combination and as monotherapy was titrated to 2000 mg. The primary endpoint was HbA1c change from baseline; secondary endpoints included change in fasting plasma glucose (FPG) and weight.In both trials, combination therapy led to significantly greater reductions in HbA1c compared

2012 EvidenceUpdates Controlled trial quality: uncertain

199. Impact of Lifestyle Intervention and Metformin on Health-Related Quality of Life: the Diabetes Prevention Program Randomized Trial Full Text available with Trip Pro

Impact of Lifestyle Intervention and Metformin on Health-Related Quality of Life: the Diabetes Prevention Program Randomized Trial Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL).To assess changes in HRQoL after interventions aimed at diabetes risk reduction.A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean (...) age 51 years, mean BMI 34 Kg/m(2); 68 % women, and 45 % members of minority groups.Intensive lifestyle (ILS) program with the goals of at least 7 % weight loss and 150 min of physical activity per week, metformin (MET) 850 mg twice daily, or placebo (PLB).HRQoL using the 36-Item Short-Form (SF-36) health survey to evaluate health utility index (SF-6D), physical component summaries (PCS) and mental component summaries (MCS). A minimally important difference (MID) was met when the mean of HRQoL

2012 EvidenceUpdates Controlled trial quality: uncertain

200. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. (Abstract)

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. In people with type 2 diabetes, a dipeptidyl peptidase-4 (DPP-4) inhibitor is one choice as second-line treatment after metformin, with basal insulin recommended as an alternative. We aimed to compare the efficacy, tolerability, and safety of insulin glargine and sitagliptin, a DPP-4 inhibitor, in patients whose disease (...) was uncontrolled with metformin.In this comparative, parallel, randomised, open-label trial, metformin-treated people aged 35-70 years with glycated haemoglobin A(1c) (HbA(1c)) of 7-11%, diagnosis of type 2 diabetes for at least 6 months, and body-mass index of 25-45 kg/m(2) were recruited from 17 countries. Participants were randomly assigned (1:1) to 24-week treatment with insulin glargine (titrated from an initial subcutaneous dose of 0·2 units per kg bodyweight to attain fasting plasma glucose of 4·0-5·5

2012 Lancet Controlled trial quality: predicted high